Merck: new clinical success for Lynparza
(CercleFinance.com) - On Wednesday AstraZeneca and its US partner Merck announced the success of a Phase III study for Lynparza in the treatment of advanced ovarian cancer.
Lynparza, a targeted cancer treatment, achieved its primary endpoint in the clinical trial by providing a statistically significant improvement in patient survival, without disease progression, compared to the current standard treatment.
AstraZeneca says that it now intends to contact international health authorities to inform them of these results.
Lynparza is already approved in about 60 countries for the treatment of certain types of ovarian cancer.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Lynparza, a targeted cancer treatment, achieved its primary endpoint in the clinical trial by providing a statistically significant improvement in patient survival, without disease progression, compared to the current standard treatment.
AstraZeneca says that it now intends to contact international health authorities to inform them of these results.
Lynparza is already approved in about 60 countries for the treatment of certain types of ovarian cancer.
Copyright (c) 2019 CercleFinance.com. All rights reserved.